Clinical Trial Update: Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports on the safety, pharmacokinetics and pharmacodynamics of subcutaneously administered concizumab in haemophilia A subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Concizumab (concizumab)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 1 | Status: COMPLETED